- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
KRAS Polyclonal Antibody / K-Ras Protein Antibody targets KRAS, a member of the RAS family of small guanosine triphosphatases that regulate intracellular signaling in response to extracellular growth factors. KRAS is encoded by the Kirsten rat sarcoma viral oncogene homolog and functions as a molecular switch, alternating between active GTP-bound and inactive GDP-bound states. Alongside HRAS and NRAS, KRAS participates in signaling pathways that influence cell proliferation, differentiation, survival, and metabolic adaptation. Its activity is tightly regulated to ensure that growth-promoting signals are transmitted for appropriate durations.
Activation of KRAS commonly occurs downstream of receptor tyrosine kinases, including members of the epidermal growth factor receptor family. Receptor stimulation recruits adaptor proteins and guanine nucleotide exchange factors such as SOS1, which facilitate the release of GDP and binding of GTP. Activated KRAS interacts with downstream effectors, including RAF kinases, to initiate the RAF-MEK-ERK signaling cascade. KRAS can also engage PI3K and other effector proteins, connecting receptor activation to pathways involved in cellular metabolism, cytoskeletal organization, and survival. GTPase-activating proteins accelerate GTP hydrolysis and help terminate these signaling responses.
The KRAS gene produces two principal splice variants, KRAS4A and KRAS4B, which share most of their amino acid sequences but differ in their C-terminal membrane-targeting regions. These differences influence intracellular localization, membrane interactions, and regulatory mechanisms. Post-translational processing, including farnesylation, is essential for normal membrane association and signaling activity. The relative expression of KRAS isoforms can vary among tissues and cellular conditions, potentially influencing their contributions to specific signaling pathways.
Oncogenic KRAS mutations frequently affect residues involved in GTP hydrolysis and regulatory protein interactions. Alterations at codons 12, 13, and 61 can promote sustained signaling through pathways that support uncontrolled proliferation. KRAS mutations are particularly common in pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma. Their biological effects depend on mutation identity, tissue context, and cooperating genetic alterations. Research into KRAS signaling has also expanded through the development of mutation-selective inhibitors and investigations of acquired therapeutic resistance. This KRAS Polyclonal Antibody provides an additional reagent for examining KRAS expression and its relationship to intracellular signaling, tumor biology, and the molecular mechanisms of oncogenic transformation.
Explore our KRAS Antibody for additional research into Kirsten Ras protein expression and RAS-dependent signaling, with Western blot validation using A549 wild-type and KRAS knockout cell lysates.
Titration of the KRAS Polyclonal Antibody / K-Ras Protein Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
A portion of amino acids 146-174 from the human protein was used as the immunogen for this KRAS Polyclonal Antibody.
Aliquot the KRAS Polyclonal Antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Kirsten Ras antibody, Kirsten rat sarcoma viral oncogene homolog antibody, KRAS proto-oncogene antibody, K-Ras GTPase antibody, KRAS p21 antibody, Kirsten Ras protein antibody, KRAS small GTPase antibody, KRAS2 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.